Fluorescence-guided Surgery in Laryngeal- and Hypopharyngeal Cancer: a Feasibility Trial (STELLAR)

The STELLAR Trial: Fluorescence-guided Surgery in Laryngeal- and Hypopharyngeal Cancer: a Feasibility Trial

This is an open-label, single-dose, prospective clinical trial. The study comprises 2 work packages. The main objective of work package I (WP-1) is to assess feasibility of Fluorescence imaing (FLI) during total laryngectomy (TLE) and to assess the optimal dose of the cRGD-ZW800-1. Work package II (WP-II) is designed to assess whether FLI can detect and decrease tumor positive margins after a TLE.

Study Overview

• Status: Not yet recruiting
• Conditions: Squamous Cell Carcinoma of the Larynx; Squamous Cell Carcinoma of the Hypopharynx
• Intervention / Treatment: Drug: CRGD-ZW800-1

Detailed Description

This is a two staged clinical trial to investigate intraoperative fluorescence imaging in patientsundergoing TLE. WP-I is a dose finding study in which 2 doses will be tested with a possibility of a third dosing group. Every dosing cohort comprises 3 patients. After WP-I, an interim analysis will be performed to decide the optimal dose.

The optimal dose will be based on the TBR and the performance in detecting the most close margin (i.e. 'the sentinel margin'). A TBR of at least 1.5 is required for the optimal dose. If a positive margin is missed with fluorescence imaging, the concerned dose will be defined as suboptimal.

WP-II is an extension cohort of the optimal dose cohort selected in WP-I. WP-II will comprise of 18 patients.

The endpoints for WP-II are:

• the rate of tumor free resection margins based on the current golden standard;
• Sensitivity, specificity and positive predictive value of FLI;
• The intraoperative change in surgical management based on FLI;
• FLI of excised cervical lymph nodes;
• Influence of previous radiotherapy on the FLI performance;
• Adverse events and toxicity after intravenous injection with cRGD-ZW800-1;

• Study Type: Interventional
• Enrollment (Estimated): 27
• Phase: Phase 2

Contacts and Locations

Study Locations

• Netherlands
  • Zuid-Holland
    • Rotterdam, Zuid-Holland, Netherlands, 3015GD
      • Erasmus Medical Center
      • Contact: Stijn Keereweer, MD, PhD

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

• Patients with biopsy-proven squamous cell Laryngeal and hypopharyngeal cancer, eligible for surgical resection of the tumor by TLE;
• ≥ 18 years of age;
• Written informed consent must be obtained;
• Sufficient knowledge of the Dutch language to understand the informed consent form;

Exclusion Criteria:

• History of a clinically significant allergy or anaphylactic reactions to any of the components of the agent;
• Other synchronous biopsy proven malignancies currently active, except for adequately treated in situ carcinoma of cervix and basal, squamous cell skin carcinoma, or other head- and neck squamous cell cancer;
• Patients pregnant or breastfeeding;
• Patients with renal insufficiency (defined as eGFR < 60);
• Patients with previous kidney transplantation or a solitary functioning kidney;
• Patients using medications that may significantly impair renal function (i.e. NSAIDs, particularly COX-2 inhibitors), that cannot be paused during the course of the study;
• Patients with ASA classification of 4 or higher;
• Patients with measured QTc of 500 ms or higher at screening;

• Patients with laboratory abnormalities defined as:

  • Aspartate AminoTransferase, Alanine AminoTransferase, Gamma Glutamyl Transferase) or Alkaline Phosphatase levels above 5 times the ULN or;
  • Total bilirubin above 3 times the ULN or;
  • Platelet count below 100 x 109/L or;
  • Hemoglobin below 4 mmol/L (females) or below 5 mmol/l (males).
• Immuno-compromised patients who do not have the ability to respond normally to an infection due to an impaired or weakened immune system, caused by either a preexisting disease or concomitant medications;

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Diagnostic
• Allocation: Non-Randomized
• Interventional Model: Sequential Assignment
• Masking: Single

Number of Arms

4

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: 0.05 mg/kg cRGD-ZW800-1; n=3. Injection of 0.05 mg/kg cRGD-ZW800-1, within 2 hours before imaging/surgery	Drug: CRGD-ZW800-1; Intravenous administration of study drug at lesat 2h prior to surgery
Experimental: 0.025 mg/kg cRGD-ZW800-1; n=3. Injection of 0.025 mg/kg cRGD-ZW800-1, within 2 hours before imaging/surgery	Drug: CRGD-ZW800-1; Intravenous administration of study drug at lesat 2h prior to surgery
Experimental: 0.01 mg/kg cRGD-ZW800-1; n=3. Injection of 0.01 mg/kg cRGD-ZW800-1, within 2 hours before imaging/surgery.	Drug: CRGD-ZW800-1; Intravenous administration of study drug at lesat 2h prior to surgery
Experimental: Expansion Cohort; n=18: expansion cohort will be added to the group of patients that had received the selected dose in WP-I.	Drug: CRGD-ZW800-1; Intravenous administration of study drug at lesat 2h prior to surgery

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
WP-II: the rate of clear tumor resection margins		Through histopathology, up to max 4 weeks post-op
WP-I: the optimal dose of cRGD-ZW800-1 for FLI of laryngeal and hypopharyngeal cancer	Based on the tumor-to-background ratio (TBR) on breadloaves. Higher TBRs indicate a better outcome	Up to 48 hours after administration (Depending on pathology grossing)

Collaborators and Investigators

• Sponsor: Erasmus Medical Center

Publications and helpful links

Helpful Links

• Guided by Light trial

Study record dates

Study Major Dates

• Study Start (Estimated): June 1, 2025
• Primary Completion (Estimated): February 1, 2027
• Study Completion (Estimated): March 1, 2027

Study Registration Dates

• First Submitted: February 21, 2023
• First Submitted That Met QC Criteria: February 21, 2023
• First Posted (Actual): March 2, 2023

Study Record Updates

• Last Update Posted (Actual): March 25, 2025
• Last Update Submitted That Met QC Criteria: February 25, 2025
• Last Verified: February 1, 2025

More Information

Terms related to this study

• Keywords: Tumour specific fluorescence imaging
• Additional Relevant MeSH Terms: Stomatognathic Diseases; Neoplasms by Site; Neoplasms; Neoplasms by Histologic Type; Head and Neck Neoplasms; Neoplasms, Glandular and Epithelial; Neoplasms, Squamous Cell; Otorhinolaryngologic Diseases; Pharyngeal Neoplasms; Otorhinolaryngologic Neoplasms; Pharyngeal Diseases; Squamous Cell Carcinoma of Head and Neck; Carcinoma; Carcinoma, Squamous Cell; Hypopharyngeal Neoplasms
• Other Study ID Numbers: NL74742.078.21

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: UNDECIDED
• IPD Plan Description: Uponr reasonable reasonable request

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No
• product manufactured in and exported from the U.S.: Yes